A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma

Blood

Volumn 120, Issue 11, 2012, Pages 2290-2296

  Perry, Anamarija M ^a   Cardesa Salzmann, Teresa M ^b   Meyer, Paul N ^a   Colomo, Luis ^b   Smith, Lynette M ^c   Fu, Kai ^a   Greiner, Timothy C ^a   Delabie, Jan ^d   Gascoyne, Randy D ^e   Rimsza, Lisa ^f   Jaffe, Elaine S ^g   Ott, German ^h   Rosenwald, Andreas ⁱ   Braziel, Rita M ^j   Tubbs, Raymond ^k   Cook, James R ^k   Staudt, Louis M ^g   Connors, Joseph M ^e   Sehn, Laurie H ^e   Vose, Julie M ^c   Loṕez Guillermo, Armando ^b   Campo, Elias ^b   Chan, Wing C ^a   Weisenburger, Dennis D ^a   more..

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f UNIVERSITY OF ARIZONA   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

ⁱ UNIVERSITY OF WÜRZBURG   (Germany)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; OSTEONECTIN; PREDNISONE; RITUXIMAB; STROMAL CELL DERIVED FACTOR 1; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SCORING SYSTEM; SIMULATION; TISSUE MICROARRAY; VALIDATION STUDY;

EID: 84866318188     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-430389     Document Type: Article

References (26)

1. Stein H, Warnke RA, Chan WC, et al. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:233-237.
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
3. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-5033. (Pubitemid 46224009)
4. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-4126. (Pubitemid 46211317)
5. Habermann TM, Weller EA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-3127. (Pubitemid 46638950)
6. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26(18):4587-4594.
7. Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, BanhamAH, Leppä S. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol. 2009;22(8):1094-1101.
8. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
9. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861. (Pubitemid 46348180)
10. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511. (Pubitemid 30082188)
11. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947. (Pubitemid 34651353)
12. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100(17):9991-9996. (Pubitemid 37087056)
13. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282. (Pubitemid 38029949)
14. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494-5502.
15. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200-207.
16. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
17. Meyer PN, Fu K, Greiner T, et al. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol. 2011;135(1):54-61.
18. Cardesa-Salzmann TM, Colomo L, Gutierrez G, et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica. 2011;96(7):996-1001.
19. Kremers WK. Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. Technical Report Series No. 80. Rochester, MN: Mayo Foundation; 2007.
20. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(6):995-1007. (Pubitemid 46638855)
21. Arnold SA, Brekken RA. SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal. 2009;3(3-4):255-273.
22. Malumbres R, Chen J, Tibshirani R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 2008;111(12):5509-5514.
23. Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2008;112(8):3425-3433.
24. Alizadeh AA, Gentles AJ, Alencar AJ, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood. 2011;118(5):1350-1358.
25. Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011;117(26):7070-7078.
26. Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011;117(18):4836-4843.